证券代码：301333 证券简称：诺思格 公告编号：2025-044 2025 年 7 月 1 日，公司发布《关于回购公司股份期限届满暨回购完成的公 告》，截至 2025 年 6 月 30 日，公司通过回购专用证券账户以集中竞价交易方式 已累计回购公司股份 1,442,000 股，约占公司总股本 96,581,256 股的 1.49%。最 高成交价为 43.15 元/股，最低成交价为 35.06 元/股，成交总金额为 56,062,734.00 诺思格（北京）医药科技股份有限公司 关于 2025 年员工持股计划非交易过户完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 诺思格（北京）医药科技股份有限公司（以下简称"公司"或"诺思格"） 于 2025 年 9 月 5 日召开第五届董事会第十三次会议及第四届监事会第十次会议， 于 2025 年 9 月 23 日召开 2025 年第二次临时股东大会，审议通过了《关于<公司 2025 年员工持股计划（草案）>及其摘要的议案》《关于<公司 2025 年员工持股 计划管理办法>的议案》等相关议案，具体内容详见公司 ...

Market Overview - The medical services sector experienced a decline of 0.9% on October 22, with Sanbo Brain Science leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the medical services sector included: - Yaokang Biological (688046) with a closing price of 17.18, up 2.81% [1] - Aoyang Health (002172) with a closing price of 4.26, up 1.91% [1] - Haochen Medical (002622) with a closing price of 3.32, up 1.84% [1] - Significant decliners included: - Sanbo Brain Science (301293) with a closing price of 57.19, down 4.67% [2] - Chengda Pharmaceutical (301201) with a closing price of 33.98, down 4.50% [2] - XD Haoyuan Medical (688131) with a closing price of 79.90, down 2.07% [2] Capital Flow - The medical services sector saw a net outflow of 615 million yuan from institutional investors, while retail investors contributed a net inflow of 370 million yuan [2][3] - Key stocks with notable capital flows included: - Kanglong Chemical (300759) with a net inflow of 46.59 million yuan from institutional investors [3] - Aoyang Health (002172) with a net inflow of 10.44 million yuan from institutional investors [3] - Yaokang Biological (688046) with a net inflow of 9 million yuan from institutional investors [3]

Core Insights - On October 10, Norscare experienced a decline of 3.08% with a trading volume of 97.24 million yuan [1] - The company reported a financing buy-in amount of 15.63 million yuan and a net financing buy of 10.66 million yuan on the same day [1] Financing Overview - As of October 10, the total financing and securities lending balance for Norscare was 10.4 million yuan, accounting for 3.45% of its market capitalization [1] - The current financing balance exceeds the 80th percentile level over the past year, indicating a high level of financing activity [1] Securities Lending Overview - On October 10, there were no shares repaid or sold in the securities lending market, resulting in a sell amount of 0 yuan [1] - The securities lending balance also stands at 0 yuan, which is above the 80th percentile level over the past year, indicating a high level of inactivity in this area [1] Company Profile - Norscare (Beijing) Medical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022 [2] - The company specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2] - The revenue composition includes: clinical trial operation services (39.25%), clinical trial site management services (34.10%), data management and statistical analysis services (13.30%), biological sample testing services (8.45%), clinical pharmacology services (3.74%), and clinical trial consulting services (1.16%) [2] Financial Performance - For the period from January to June 2025, Norscare achieved a revenue of 380 million yuan, reflecting a year-on-year growth of 0.18% [2] - The net profit attributable to the parent company was 61.12 million yuan, representing a year-on-year increase of 4.45% [2] Shareholder Information - As of June 30, 2025, Norscare had 10,400 shareholders, an increase of 2.06% from the previous period [2] - The average number of circulating shares per shareholder was 5,486, a decrease of 1.97% from the previous period [2] - The company has distributed a total of 49.50 million yuan in dividends since its A-share listing [3]

Group 1 - He Eye Hospital's subsidiary has signed a share subscription agreement to acquire Japan's Ido Medical, marking a significant step in its international expansion in ophthalmology [1] - The investment requires approval from multiple regulatory bodies in both China and Japan, highlighting the complexities and high barriers of cross-border medical investments [1] Group 2 - Jin Cheng Pharmaceutical's actual controller and chairman, Zhao Yeqing, received a notice of administrative penalty for violating securities laws, resulting in a fine of 3 million yuan, with Zhao personally liable for 1.5 million yuan and a four-year market ban [2] - This incident raises concerns about the company's governance and internal control, potentially impacting its reputation and market confidence [2] Group 3 - Two senior executives at Nuo Si Ge have resigned from their vice president positions but will continue to lead subsidiary companies, indicating an internal management restructuring aimed at enhancing operational efficiency and strategic execution [3] Group 4 - Haikang Pharmaceutical's subsidiary has received acceptance for an IND application for HSK36357 capsules, a new small molecule drug with independent intellectual property rights, showing significant analgesic effects and potential in treating muscular dystrophy [4] - The dual mechanism of HSK36357 could provide a new treatment option for patients with Duchenne muscular dystrophy, indicating substantial market potential if clinical validation is achieved [4] Group 5 - Changfeng Pharmaceutical has successfully listed on the Hong Kong Stock Exchange with an IPO price of 14.75 HKD per share, focusing on the research, production, and commercialization of inhalation technologies for respiratory diseases [5] - The company's stock surged over 200% on its debut, reflecting strong market recognition of its leading position in the inhalation drug sector [6]

关于高级管理人员变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：301333 证券简称：诺思格 公告编号：2025-043 诺思格（北京）医药科技股份有限公司 特此公告。 诺思格（北京）医药科技股份有限公司董事会 2025 年 10 月 10 日 1 近日，诺思格（北京）医药科技股份有限公司（以下简称"公司"）董事会 收到公司首席医学官、副总经理李继刚先生与公司副总经理刘萍女士分别提交的 关于辞任公司副总经理的申请。李继刚先生因工作重心调整申请辞去公司副总经 理职务，其申请自提交董事会之日起生效。李继刚先生仍将继续担任公司首席医 学官、子公司南京艾科曼信息技术有限公司总经理（兼法定代表人）职务，并专 注于公司医学事务与子公司的管理工作。刘萍女士因工作重心调整申请辞去公司 副总经理职务，其申请自提交董事会之日起生效。刘萍女士仍将继续担任子公司 北京领初医药科技有限公司总经理职务，并专注于公司临床药理事务及子公司管 理工作。 截至本公告披露日，李继刚先生持有公司股份 31,950 股，约占公司总股本 的 0.03%。刘萍女士持有公司股份 27 ...

Group 1 - The CRO sector led the market with a rise of 3.5% on September 30 [1] - Haoyuan Pharmaceutical increased by 6.58% [1] - WuXi AppTec rose by 6.21% [1] - Boteng Co., Ltd. saw an increase of 4.99% [1] - MediSci and Northgrip, as well as Chengda Pharmaceutical, all experienced gains exceeding 4% [1]

Core Viewpoint - Norska's stock price has shown a positive trend with an 8.48% increase year-to-date, reflecting investor confidence in the company's growth potential in the clinical trial services sector [2]. Company Overview - Norska (Beijing) Pharmaceutical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022. The company is located in Haidian District, Beijing [2]. - The company's main business includes clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2]. - Revenue composition: Clinical trial operation services (39.25%), clinical trial site management services (34.10%), data management and statistical analysis services (13.30%), biological sample testing services (8.45%), clinical pharmacology services (3.74%), and clinical trial consulting services (1.16%) [2]. Financial Performance - For the first half of 2025, Norska achieved operating revenue of 380 million yuan, a year-on-year increase of 0.18%, and a net profit attributable to shareholders of 61.12 million yuan, up 4.45% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 49.50 million yuan [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 10,400, with an average of 5,486 circulating shares per person, a decrease of 1.97% from the previous period [2]. - New significant shareholders include Hong Kong Central Clearing Limited and two funds from Zhonggeng, indicating growing institutional interest [3].

2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301333 证券简称：诺思格 公告编号：2025-042 诺思格（北京）医药科技股份有限公司 特别提示： 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 网络投票时间：2025 年 9 月 23 日，其中通过深圳证券交易所交易系统进行 投票的时间为 2025 年 9 月 23 日上午 9:15-9:25，9:30-11:30 和下午 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的时间为 2025 年 9 月 23 日上午 9:15- 下午 15:00 期间。 2、现场会议召开地点：北京市海淀区车公庄西路 19 号华通大厦 B 座北塔 11 层公司会议室。 3、会议召开和表决方式：本次会议采取现场记名投票与网络投票相结合的 方式。 4、股东大会的召集人：公司董事会。 5、会议主持人：董事长武杰先生。 6、本次股东大会的召集和召开符合《中华人民共和国公司法》《上市公司 股东会规则》《深圳证券交易所创业板 ...

一、 本次股东大会的召集、召开程序 1.1 本次股东大会由公司董事会召集。 公司董事会于 2025 年 9 月 5 日召开第五届董事会第十三次会议，审议通 过了《关于<公司 2025 年员工持股计划（草案）>及其摘要的议案》《关 于<公司 2025 年员工持股计划管理办法>的议案》《关于提请股东大会授 权董事会办理公司 2025 年员工持股计划相关事宜的议案》《关于补选公 上海君澜律师事务所 关于诺思格（北京）医药科技股份有限公司 2025 年第二次临时股东大会的法律意见书 致：诺思格（北京）医药科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》《上市公司股东会规则》（以下简称"《股东会规则》"）等法 律、法规、规章、规范性文件及《诺思格（北京）医药科技股份有限公司章程》 （以下简称"《公司章程》"）的规定，上海君澜律师事务所（以下简称"本所"） 接受诺思格（北京）医药科技股份有限公司（以下简称"公司"）的委托，指派 本所律师出席公司2025年第二次临时股东大会（以下简称"本次股东大会"）， 并就本次股东大会的召集、召开程序及表决程序、表决结果等事项出具本法律 ...

Group 1 - The core point of the news is that Norscare's stock has experienced a decline of 5.08% on September 23, with a total market value of 5.072 billion yuan and a cumulative drop of 4.6% over the past four days [1] - Norscare (Beijing) Pharmaceutical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022. The company specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [1] - The revenue composition of Norscare's main business includes: clinical trial operation services (39.25%), clinical trial site management services (34.10%), data management and statistical analysis services (13.30%), biological sample testing services (8.45%), clinical pharmacology services (3.74%), and clinical trial consulting services (1.16%) [1] Group 2 - From the perspective of fund holdings, one fund under Dongcai has a significant position in Norscare, with Dongcai Vision Growth Mixed Initiation A (018088) holding 12,400 shares, accounting for 4.85% of the fund's net value, ranking as the fifth-largest holding [2] - The fund has experienced a floating loss of approximately 34,800 yuan today, with a cumulative floating loss of 33,100 yuan during the four-day decline [2] - Dongcai Vision Growth Mixed Initiation A (018088) was established on April 11, 2023, with a latest scale of 9.6956 million yuan, and has achieved a year-to-date return of 46.64% [2]